FDA Adverse Event Injury Summary report: N

MICRO-V ALTERNANS SENSORS

MDR report key: 974748 · Received December 31, 2007

Report

Report Number
1225215-2007-00002
Event Type
Injury
Date Received
December 31, 2007
Date of Event
July 20, 2007
Report Date
December 31, 2007
Manufacturer
CAMBRIDGE HEART, INC.
Product Code
DRX
PMA / PMN Number
K002230
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

INSPECTION RECORDS FOR LOT #542791 SHOW THAT THE SENSORS PASSED INSPECTION. WE WILL FILE AN UPDATED REPORT WHEN ADDITIONAL INFO BECOMES AVAILABLE.

Description of Event or Problem · 1

10/22/07: CARDIOVASCULAR TECHNICIAN ASKED CAMBRIGDGE HEART FOR A LIST OF ALTERNANS SENSOR GEL COMPONENTS BECAUSE 4 OF APPROX 130 PTS HAD REPORTED RED WELTS AFTER MICROVOLT T-WAVE ALTERNANS TESTING. TECH SAID NONE OF THE PTS HAD SOUGHT ADDITIONAL TREATMENT. HE WAS ADVISED NOT TO OVER-ABRADE THE PTS' SKIN. ON 11/2/07: ALTHOUGH THE COMPONENT LIST WAS FAXED TO TECH, HE PHONED TO SAY HE HAD NOT RECEIVED IT. HE ALSO SAID, HE HAD TAKEN THE ADVICE REGARDING ABRASION AND THAT SKIN IRRITATION WAS LESS COMMON. HOWEVER, A CARDIOLOGIST AT THE SITE, STATED THAT THE DAY BEFORE, A PT RETURNING FOR FOLLOW-UP AFTER A 4-MONTH EARLIER, MTWA TEST HAD RED MARKINGS THAT HER DOCTOR CLASSIFIED AS PERMANENT SCARS. HE REQUESTED THAT A CAMBRIDGE HEART REP BE SENT TO THE SITE. ON 12/7/07: A CAMBRIDGE HEART EMPLOYEE MET WITH DR. AND LEARNED THAT THE PT, A LIGHT-SKINNED AFRICAN AMERICAN WITH NO KNOWN ALLERGIES OR OTHER MEDICAL ISSUES, HAD THE SENSORS ON FOR NO MORE THAN AN HOUR. DR. SAID, HE OBSERVED AN AREA OF HYPERPIGMENTATION AT THE TOP OF HER BREASTBONE AND REFERRED HER TO A DERMATOLOGIST. BASED ON THE INFO RECEIVED DURING THIS VISIT, CAMBRIDGE HEART DETERMINED THAT THIS IS A REPORTABLE EVENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 MICRO-V ALTERNANS SENSORS ELECTORDE, ELECTROCARDIOGRAPH DRX CAMBRIDGE HEART, INC. NA 542791

Patients

Seq Age Sex Outcome Treatment
1 49 YR Required Intervention